Who are Epsilogen's investors?

Epsilogen's investors include 3B Future Health Fund, AlbionVC, ALSA Ventures, BioGeneration Ventures, Epidarex Capital, Global BioAccess Fund, Novartis Venture Fund, UCL Technology Fund.

Epsilogen

Founded 2016 · 33 employees on LinkedIn · 8 known investors

Find your way into Epsilogen

Paths you didn't know you had: your email and LinkedIn already hold routes to the Epsilogen team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is in clinical development for ovarian cancer.

Biotech Healthtech

Founders & leadership

Tim WilsonChief Executive Officer

Kevin FitzGeraldChief Scientific Officer

Cristina OlivaChief Medical Officer

Nick Robbins-Cherry Chief Financial OfficerNick Robbins-Cherry is a Chartered Accountant with an MBA who has held CFO roles at publicly listed and clinical-stage pharmaceutical companies, including Midatech Pharma (which listed on AIM and NASDAQ) and Epsilogen, where he led the acquisition of TigaTx. He has prior finance and commercial experience across pharmaceuticals, technology services, software, and telecoms sectors.

Elizabeth HardakerChief Translational Science Officer

Investors · 8

3B Future Health Fundlisted by 3B Future Health FundMonaco · $12M

How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

AlbionVClisted by AlbionVCLondon

How we know: AlbionVC's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

ALSA Ventureslisted by ALSA VenturesLondon

BioGeneration Ventureslisted by BioGeneration VenturesNaarden

How we know: BioGeneration Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Epidarex Capitallisted by Epidarex CapitalBethesda · $2.5M – $6.3M

How we know: Epidarex Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Global BioAccess Fundlisted by Global BioAccess FundNew York · $10M

Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

UCL Technology Fundlisted by UCL Technology FundLondon · $320K – $9M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Related companies · 2

Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Epsilogen.

Frequently asked questions

What does Epsilogen do?: Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is in clinical development for ovarian cancer.
Who are Epsilogen's investors?: Epsilogen's investors include 3B Future Health Fund, AlbionVC, ALSA Ventures, BioGeneration Ventures, Epidarex Capital, Global BioAccess Fund, Novartis Venture Fund, UCL Technology Fund.